(Q37682875)

22 August 2017

1 reference

title

Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity (English)

1 reference

22 August 2017

1 reference

1 reference

Jasvinder A Singh

2

0 references

Vibeke Strand

series ordinal

1

object named as

Vibeke Strand

1 reference

22 August 2017

publication date

1 January 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

70

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

121-145

1 reference

Interpreting treatment effects in randomised trials

22 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11531980-000000000-00000

Worker productivity outcome measures in arthritis.

21 January 2018

1 reference

12 December 2020

Predicting the short form-6D preference-based index using the eight mean short form-36 health dimension scores: estimating preference-based health-related utilities when patient level data are not available

1 reference

12 December 2020

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

12 December 2020

The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases

1 reference

12 December 2020

Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specific Work Productivity Survey (WPS-RA).

1 reference

12 December 2020

1 reference

12 December 2020

The estimation of a preference-based measure of health from the SF-36.

1 reference

12 December 2020

Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.

1 reference

12 December 2020

The relationship between productivity and health-related QOL: an exploration.

1 reference

12 December 2020

Improvement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodies

1 reference

12 December 2020

Longer term benefits of treating rheumatoid arthritis: assessment of radiographic damage and physical function in clinical trials

1 reference

12 December 2020

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

1 reference

12 December 2020

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group st

1 reference

12 December 2020

Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy

1 reference

12 December 2020

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

1 reference

12 December 2020

Association between etanercept use and employment outcomes among patients with rheumatoid arthritis

1 reference

12 December 2020

1 reference

12 December 2020

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

1 reference

12 December 2020

1 reference

12 December 2020

1 reference

12 December 2020

Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life.

1 reference

12 December 2020

Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA.

1 reference

12 December 2020

Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis

1 reference

12 December 2020

Use of "spydergrams" to present and interpret SF-36 health-related quality of life data across rheumatic diseases

1 reference

12 December 2020

The OMERACT filter for Outcome Measures in Rheumatology

1 reference

12 December 2020

Benchmarking: the five year outcome of rheumatoid arthritis assessed using a pain score, the Health Assessment Questionnaire, and the Short Form-36 (SF-36) in a community and a clinic based sample

1 reference

12 December 2020

Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment

1 reference

12 December 2020

A comparison of the EQ-5D and SF-6D across seven patient groups

1 reference

12 December 2020

Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial

1 reference

12 December 2020

Evaluation of health-related quality of life of rheumatoid arthritis patients treated with celecoxib.

1 reference

12 December 2020

Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.

1 reference

12 December 2020

1 reference

12 December 2020

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

12 December 2020

The relationship of medical, demographic and psychosocial factors to direct and indirect health utility instruments in rheumatoid arthritis.

1 reference

12 December 2020

Deriving a preference-based single index from the UK SF-36 Health Survey.

1 reference

12 December 2020

Comparison of the Health Assessment Questionnaire (HAQ) and the modified HAQ (MHAQ) in patients with rheumatoid arthritis.

1 reference

12 December 2020

Working status among Dutch patients with rheumatoid arthritis: work disability and working conditions.

1 reference

12 December 2020

1 reference

12 December 2020

[Productivity costs of rheumatoid arthritis in Germany. Cost composition and prediction of main cost components].

1 reference

12 December 2020

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

1 reference

12 December 2020

Quality of life in patients with rheumatoid arthritis: does abatacept make a difference?

1 reference

12 December 2020

Assessing utility values in rheumatoid arthritis: A comparison between time trade-off and the EuroQol

1 reference

12 December 2020

A comparative review of generic quality-of-life instruments

1 reference

12 December 2020

Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial

1 reference

12 December 2020

Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial

1 reference

12 December 2020

A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis

1 reference

12 December 2020

Health status instruments / utilities.

1 reference

12 December 2020

Work limitations in the outcome assessment of rheumatoid arthritis

1 reference

12 December 2020

Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study

1 reference

12 December 2020

Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis

1 reference

12 December 2020

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

1 reference

12 December 2020

Joint damage and disability in rheumatoid arthritis: an updated systematic review

1 reference

12 December 2020

Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D).

1 reference

12 December 2020

Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials.

1 reference

12 December 2020

The course of rheumatoid arthritis and predictors of psychological, physical and radiographic outcome after 5 years of follow-up

1 reference

12 December 2020

Quality-of-life assessment in rheumatoid arthritis

1 reference

12 December 2020

Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate

1 reference

12 December 2020

Systematic review of studies of productivity loss due to rheumatoid arthritis

1 reference

12 December 2020

Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial.

1 reference

12 December 2020

1 reference

12 December 2020

Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations

1 reference

12 December 2020

Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate

1 reference

12 December 2020

Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice

1 reference

12 December 2020

How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS)

1 reference

12 December 2020

Productivity costs among patients with rheumatoid arthritis: the influence of methods and sources to value loss of productivity

1 reference

12 December 2020

Limited correlation between the Health Assessment Questionnaire (HAQ) and EuroQol in rheumatoid arthritis: questionable validity of deriving quality adjusted life years from HAQ.

1 reference

12 December 2020

Measuring health status in British patients with rheumatoid arthritis: reliability, validity and responsiveness of the short form 36-item health survey (SF-36).

1 reference

12 December 2020

Household income and earnings losses among 6,396 persons with rheumatoid arthritis.

1 reference

12 December 2020

Reliability of the Health Utilities Index--Mark III used in the 1991 cycle 6 Canadian General Social Survey Health Questionnaire.

1 reference

12 December 2020

Use of the short form 36 (SF36) for health status measurement in rheumatoid arthritis

1 reference

12 December 2020

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

1 reference

12 December 2020

A comparison of four indirect methods of assessing utility values in rheumatoid arthritis

1 reference

12 December 2020

Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II.

1 reference

12 December 2020

The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument.

1 reference

12 December 2020

Validity of Euroqol--a generic health status instrument--in patients with rheumatoid arthritis. Economic and Health Outcomes Research Group.

1 reference

12 December 2020

Infliximab treatment maintains employability in patients with early rheumatoid arthritis

1 reference

12 December 2020

The relationship between social deprivation, disease outcome measures, and response to treatment in patients with stable, long-standing rheumatoid arthritis.

1 reference

12 December 2020

Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis

1 reference

12 December 2020

Personal and economic burden of late-stage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patient's perspective

1 reference

12 December 2020

Improvement and longterm maintenance of quality of life during treatment with adalimumab in severe rheumatoid arthritis

1 reference

12 December 2020

A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment.

1 reference

12 December 2020

Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group

1 reference

12 December 2020

Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation

1 reference

12 December 2020

Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group

1 reference

12 December 2020

Comparison of employability outcomes among patients with early or long-standing rheumatoid arthritis

1 reference

12 December 2020

Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available).

1 reference

12 December 2020

Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treat

1 reference

12 December 2020

Validating and assessing the sensitivity of the Health Assessment Questionnaire-Disability Index-derived Short Form-6D in patients with early aggressive rheumatoid arthritis

1 reference

12 December 2020

Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized cont

1 reference

12 December 2020

Treatment impact on estimated medical expenditure and job loss likelihood in rheumatoid arthritis: re-examining quality of life outcomes from a randomized placebo-controlled clinical trial with abatacept

1 reference

12 December 2020

Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial.

1 reference

12 December 2020

10.2165/11531980-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

22 August 2017

1029531428

0 references

1 reference